Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Attikon Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06889454CT.gov Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS | — | Recruiting | — | — | — |
NCT03843736CT.gov The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS. | — | Unknown | — | — | — |
NCT03043924CT.gov Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) | — | Completed | — | — | — |
NCT00842140CT.gov Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Levonorgestrel (this asset) | Attikon Hospital | Approved | BB · 68 |
| Semaglutide | Methodist Health System | P4 | BBB |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Ethinyl Estradiol | Ege University | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Cetrotide | Ahmed Saad | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Levonorgestrel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P4 | BB · 65 |
| Major Depressive Disorder | — | P4 | B · 60 |
| Epilepsy | — | P4 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Levonorgestrel in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/levonorgestrel-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →